Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of RLY5016 for hyperkalemia in hypertensive patients with diabetic nephropathy on ACEI/ARB ± spironolactone
2011-000165-12Phase 2Completed
- Sponsor
- Relypsa, Inc.
- Start
- Mar 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of patiromer in hyperkalemia, hypertension (HTN) and diabetic glomerulosclerosis, sponsored by Relypsa, Inc. Primary endpoint: Mean change in serum potassium from baseline to week 4. Started Mar 2011; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemiahypertension (HTN)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2011-000165-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000165-12.